Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflam...
Q1 2026
May 7, 2026
FY 2025
Mar 24, 2026
Q4 2025
Q3 2025
Nov 12, 2025
Q2 2025
Aug 12, 2025